Search clinical trials for: advanced bladder cancer which showed resistance for standard treatments

Total 381334 results

NGM Biopharmaceuticals, Inc
Merck Sharp & Dohme LLC

Recruiting

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

Melanoma | Renal Cell Carcinoma | Cervical Cancer | Breast Cancer | Gastric Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Mesothelioma | Squamous Cell Carcinoma of Head and Neck | Cholangiocarcinoma | Non-small Cell Lung Cancer | Colorectal Carcinoma | Bladder Urothelial Cancer | Endocervical...

United States
Wuhan Union Hospital, China

Recruiting

A Single-Arm Phase II Exploratory Clinical Study of Pemigatinib in the Treatment of Advanced Gastric and Colorectal Cancer Patients With FGFR Alterations Who Have Failed Standard Therapy

Gastric and Colorectal Cancer

China
National Health Research Institutes, Taiwan
National Taiwan University Hospital; Chang Gung Memorial Hospital; Kaohsiung... and other collaborators

Recruiting

Lenvatinib Plus Paclitaxel for Patients With Advanced Biliary Tract Cancer Who Failed to Gemcitabine-based Treatment (LenPac)

Advanced Biliary Tract Cancer

Taiwan
University of Chicago

Recruiting

Evaluating Personalized Therapeutics Clinic (PTC) on Drug-Drug Interactions and Drug-Gene Interactions

Cancer | Advanced Solid Tumor | Advanced Cancer | Behavior Disorders | Mental Health Issue

United States
Peking University

Recruiting

JMT101 Combined With Afatinib in Patients With Advanced Esophageal Squamous Cell Carcinoma After Standard Therapy

Esophageal Squamous Carcinoma

China
Regeneron Pharmaceuticals

Recruiting

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

Multiple Myeloma

United States, Spain, France, Greece
Memorial Sloan Kettering Cancer Center
Rockefeller University; Pin Down Bladder Cancer Research Foundation

Recruiting

Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment

Non-muscle Invasive Bladder Cancer

United States
Pfizer

Recruiting

MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma

Multiple Myeloma

United States, Canada
Medicenna Therapeutics, Inc.
Merck Sharp & Dohme LLC

Recruiting

A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1)

Clear Cell Renal Cell Carcinoma | Cervical Cancer | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | Fallopian Tube Cancer | Solid Tumor | Squamous Cell Carcinoma of Head and Neck | Bladder Cancer | Skin Cancer | Triple Negative Breast Cancer | Advanced Solid Tumor | Primary Peritoneal Cancer | Endometrial Carcinoma and other conditions

United States, Australia, Korea, Republic of, Canada
Protara Therapeutics

Recruiting

Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer (Phase 1a) (ADVANCED-1)

Non-muscle Invasive Bladder Cancer

United States, Moldova, Republic of, Romania, Ukraine
Protara Therapeutics

Recruiting

Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer (ADVANCED-1)

Non-muscle Invasive Bladder Cancer

United States
UNICANCER

Recruiting

Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients With Metastatic Cancer in Response After 6 Months of Standard IO (MOIO)

Melanoma | Renal Cell Carcinoma | Head and Neck Cancer | Hepatocellular Carcinoma | Lung Cancer Metastatic | Bladder Cancer | Triple Negative Breast Cancer | Merkel Cell Carcinoma

France
National Cancer Institute (NCI)

Recruiting

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

Recurrent Head and Neck Squamous Cell Carcinoma | Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma | Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Stage IV Hypopharyngeal... and other conditions

United States
Exact Sciences Corporation

Recruiting

ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk

Hepatitis B | Hepatocellular Carcinoma | Cirrhosis | Liver Cancer | Hepatocellular Cancer

United States
National Cancer Institute (NCI)

Recruiting

Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

Advanced Extrapulmonary Neuroendocrine Carcinoma | Metastatic Extrapulmonary Neuroendocrine Carcinoma | Recurrent Extrapulmonary Neuroendocrine Carcinoma | Unresectable Extrapulmonary Neuroendocrine Carcinoma

United States
Cancer Research UK
Hummingbird Bioscience

Recruiting

HMBD-001 in Advanced HER3 Positive Solid Tumours

Melanoma | Cervical Cancer | Gastric Cancer | Pancreatic Cancer | Ovarian Cancer | Hepatocellular Carcinoma (HCC) | Bladder Cancer | Triple Negative Breast Cancer | Endometrial Cancer | Castration-resistant Prostate Cancer | Non-small Cell Lung Cancer (NSCLC) | Oesophageal Cancer | RAS Wild Type Colorectal Cancer | Squamous Cell Cancer of the Head and Neck

United Kingdom
M.D. Anderson Cancer Center
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute...

Recruiting

Multicomponent Physical Activity Intervention for the Reduction of Psychosocial Distress in Cancer Patients

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Anxiety Disorder

United States
M.D. Anderson Cancer Center

Recruiting

Cetuximab for the Treatment of Advanced Unresectable or Metastatic Chordoma

Chordoma | Metastatic Chordoma | Unresectable Chordoma

United States
AGO Study Group
European Network of Gynaecological Oncological Trial Groups (ENGOT)

Recruiting

Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

Germany
GI Innovation, Inc.
Merck Sharp & Dohme LLC

Recruiting

GI-101 as a Single Agent or in Combination With Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumors

Melanoma | Sarcoma | Renal Cell Carcinoma | Cervical Cancer | Urinary Bladder Cancer | Vulvar Cancer | Advanced Solid Tumor | Metastatic Solid Tumor | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma | Merkel Cell Carcinoma | Vaginal Cancer | Microsatellite Stable...

Korea, Republic of, United States
Tarus Therapeutics, Inc.

Not yet recruiting

TT-4 as a Single Agent in Subjects With Advanced Selected Solid Tumors

Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer
Samsung Medical Center

Recruiting

Pembrolizumab With Standard Cytotoxic Chemotherapy in Treatment Naive NSCLC Patients With Asymptomatic Brain Metastases (PHOEBS)

Non-small Cell Lung Cancer

Korea, Republic of
Lucid Lane, Inc
M.D. Anderson Cancer Center

Recruiting

Digital and Behavioral Tele-Health Tapering Program for Lowering Dependence on Opioids in Patients Undergoing Surgery

Malignant Solid Neoplasm | Malignant Thoracic Neoplasm | Malignant Head and Neck Neoplasm | Malignant Abdominal Neoplasm

United States
National Cancer Institute (NCI)

Recruiting

Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy

Metastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Recurrent Bladder Urothelial Carcinoma | Recurrent Renal Pelvis Urothelial Carcinoma | Recurrent... and other conditions

United States
M.D. Anderson Cancer Center

Recruiting

Nivolumab for the Treatment of Patients With Metastatic Urothelial Cancer With ARID1A Mutation and Stratify Response Based on CXCL13 Expression

Metastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Recurrent Bladder Urothelial Carcinoma | Recurrent Renal Pelvis Urothelial Carcinoma | Recurrent... and other conditions

United States
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Clinical Study of TQB3616 Capsules Combined With Anlotinib Hydrochloride Capsules or Standard Chemotherapy Second-line and Above in the Treatment of Advanced Lung Cancer

Advanced Lung Carcinoma

China
Janssen Research & Development, LLC

Recruiting

A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4)

Urinary Bladder Neoplasms

United States, Korea, Republic of, France, Israel, Spain, Italy, United Kingdom, Belgium, Netherlands, Germany
M.D. Anderson Cancer Center

Recruiting

Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Advanced Malignant Solid Neoplasm | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Clinical Stage III Cutaneous Melanoma AJCC v8 and other conditions

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Recruiting

PLAN Intervention to Enhance Engagement of Latino Cancer Patients in Advanced Care Planning

Locally Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
Seagen Inc.
Merck Sharp & Dohme LLC

Recruiting

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

Urothelial Carcinoma

United States, Canada, United Kingdom, Japan, Spain, Australia, Argentina, Chile, Israel, Belgium
Emory University
National Cancer Institute (NCI); Exelixis

Recruiting

Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer

Metastatic Urothelial Carcinoma | Locally Advanced Urothelial Carcinoma | Unresectable Urothelial Carcinoma | Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation

United States
Zhujiang Hospital

Recruiting

Neoadjuvant Toripalimab in Combination With Gemcitabine and Cisplatin Therapy in Local Advanced Bladder Cancer Subjects

Urinary Bladder Cancer

China
Nanfang Hospital of Southern Medical University

Recruiting

Relationship Between Standard Treatment Efficacy and The Tumor Microenvironment in Advanced Gastric Cancer

Gastric Cancer

China
Emory University
National Cancer Institute (NCI)

Recruiting

Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma

Metastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Stage IV Bladder Cancer AJCC v8 | Stage IV Renal Pelvis Cancer AJCC v8 | Stage IV Ureter Cancer... and other conditions

United States
Institut d'Investigació Biomèdica de Bellvitge

Recruiting

Infectious Diseases Experts as Part of the Antibiotic Stewardship Team in Primary Care (IDASP)

Infectious Disease

Spain
Institut Curie

Recruiting

Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer. (PACT-01)

Carcinoma, Non-Small-Cell Lung | Advanced Cancer

France
National Cancer Institute (NCI)

Recruiting

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

Lymphoplasmacytic Lymphoma | Ann Arbor Stage III Diffuse Large B-Cell Lymphoma | Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma | High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Grade 3b Follicular... and other conditions

United States
IDEAYA Biosciences

Recruiting

Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion

Solid Tumor

United States, Taiwan, Korea, Republic of, France, Spain, Australia, Germany
Weprom
Pfizer; FLGXPL

Recruiting

A Web-mediated Follow-up With the Web-application KidneyPRO Versus Standard Follow-up for Patients With Advanced Renal Cell Carcinoma Treated With Axitinib/Pembrolizumab in First Line (AxiPRO)

Renal Cell Carcinoma Metastatic

France
University Hospital, Ghent
Kom Op Tegen Kanker

Recruiting

Evaluating the Impact of 18F-FDG-PET-CT on Risk Stratification and Treatment Adaptation for Patients With Muscle Invasive Bladder Cancer (EFFORT-MIBC)

Muscle-Invasive Bladder Carcinoma

Belgium
Dragonboat Biopharmaceutical Company Limited
Fudan University

Recruiting

the Efficacy and Safety of LDP in Patients With Urinary and Male Genital Tumors

Bladder Cancer | Renal Carcinoma | Advanced Penile Carcinoma

China
Keythera Pharmaceuticals (Australia) Pty Ltd

Recruiting

A Study of KF-0210 in Advanced Solid Tumors Patients

Gastric Cancer | Colorectal Cancer | Lung Cancer | Bladder Cancer | Advanced Solid Tumor | Squamous Cell Carcinoma of the Esophagus

Australia
Universitaire Ziekenhuizen KU Leuven
AZ Sint-Jan AV; General Hospital Groeninge; AZ Sint-Blasius Dendermonde

Recruiting

Prospective Prostate Cancer and Patient-reported Outcomes Registry (Prosquare)

Prostate Cancer | Adenocarcinoma of the Prostate | Locally Advanced Prostate Carcinoma | Locally Advanced Prostate Adenocarcinoma

Belgium
PureTech

Recruiting

LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors

Head and Neck Cancer | Colorectal Cancer | Pancreatic Cancer | Solid Tumor | Metastatic Cancer | Urothelial Carcinoma

United States
Centre Oscar Lambret
Laboratoire PRISM - Michel SALZET

Recruiting

Omic Technologies to Track Resistance to Palbociclib in Metastatic Breast Cancer (OMERIC)

Advanced Breast Cancer

France
AstraZeneca

Recruiting

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (PETRA)

Cervical Cancer | Breast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Prostate Cancer | Bladder Cancer | Endometrial Cancer | Non-small Cell Lung Cancer | Biliary Cancer | Additional Indications Below for Module 4 and 5 | Small Cell Lung Cancer Only in Module 5

Canada, China, Spain, Korea, Republic of, Italy, Poland, United States, Australia, United Kingdom, Japan, Hungary, Russian Federation, Czechia
Ascentage Pharma Group Inc.

Recruiting

APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma

Advanced Pancreatic Cancer

China
University of Kansas Medical Center
Vikor Scientific

Not yet recruiting

Comparative Microbial Analysis of Cystitis in Non-muscle-invasive Bladder Cancer Patients Using Vikor Scientific Urine-ID Testing Menu (IDTM) and Standard Laboratory Culture (VS-UrineID)

Urinary Tract Infections | Bladder Cancer

United States
National Cancer Institute (NCI)

Recruiting

Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer

Metastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Stage IV Bladder Cancer AJCC v8 | Stage IV Renal Pelvis Cancer AJCC v8 | Stage IV Ureter Cancer... and other conditions

United States
Shanghai Junshi Bioscience Co., Ltd.

Not yet recruiting

A Study Evaluating Toripalimab Injection Combined With Standard Chemotherapy as a First-line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma

Locally Advanced or Metastatic Urothelial Carcinoma

China

Search clinical trials for: advanced bladder cancer which showed resistance for standard treatments

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Indonesia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations